Table 2.

Comparison of clinicopathological characteristics between BRCA1/2 status and ER IHC status.

Category		BRCA1/2 status			ER IHC status
		Wild type (n = 137)	Mutation status (n = 26)	P-value	Bilateral concordant (n = 127)	Bilateral discordant (n = 36)	P-value
Age at menarche	≤ 14 years	60	13	0.56	57	16	0.963
	>14 years	77	13		70	20
Menopause status	Premenopausal	50	12	0.352	52	10	0.151
	Menopausal	87	14		75	26
Age	≤ 50 years	49	15	0.036	56	8	0.018
	>50 years	88	11		71	28
Family history	Breast cancer	11	7	0.005	14	4	0.988
	No history	126	16		113	32
pT	pTis/pT1	54	12	0.521	52	14	0.824
	pT2/pT3	83	14		75	22
BMI	<24	91	18	0.78	92	17	0.005
	≥24	46	8		35	19
Number of pregnancies	≤ 2 times	77	11	0.192	65	23	0.177
	>2 times	60	15		62	13
pN	LN-negative	98	14	0.075	89	23	0.48
	LN-positive	39	12		38	13
Histopathology	Lobular component	21	2	0.537	19	4	0.558
	No lobular component	116	24		108	32
Invasive component	Bilateral invasive carcinoma	78	17	0.652	73	22	0.909
	Unilateral invasive carcinoma	44	6		40	10
	Bilateral carcinoma in situ	15	3		14	4
ER status	Bilateral positive	89	17	0.022	–	–
	Bilateral discordant	34	2		–	–
	Bilateral negative	14	7		–	–
BRCA1/2 status	Wide type	–	–		103	34	0.07
	Mutation type	–	–		24	2

pT, pathological tumor stage; pN, pathological lymphnode stage; BMI, Body Mass Index.